KCTD17

Across TCGA pan-cancer cohorts, KCTD17 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of KCTD17’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where KCTD17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KCTD17 is over-expressed in tumor, although a few such as KICH and BLCA show the opposite, repressed pattern.

HNSC, KIRC, and LIHC are the cancer types where KCTD17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KCTD17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	+1.098	<.001	12	view →
KIRC	Male	III,IV	+0.751	<.001	11	view →
LIHC	Female	II,III,IV	+2.781	<.001	9	view →
THCA	Male	III,IV	+0.885	<.001	7	view →
BRCA	All	All	+0.462	<.001	6	view →
KICH	Female	II,III,IV	−1.668	<.001	5	view →
STAD	All	II,III,IV	+0.883	.004	5	view →
COAD	Female	All	+0.496	.005	4	view →
CHOL	All	All	+3.875	<.001	3	view →
ESCA	All	All	+1.424	.001	3	view →
BLCA	Male	IV	−1.370	.016	2	view →
PRAD	All	All	−0.983	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

KCTD17–HNSC

Open the HNSC breakdown →